New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT06082960

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times

Summary

This early-phase study tests a new drug called GS-9911, given alone or with an immunotherapy drug, in 45 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. This is a first step to see if the approach is worth studying further.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • Smilow Cancer Hospital Phase 1 Unit

    New Haven, Connecticut, 06520, United States

  • South Texas Accelerated Research Therapeutics, LLC

    San Antonio, Texas, 78229, United States

  • University Health Network, Princess Margaret Cancer Centre

    Toronto, M5G, Canada

Conditions

Explore the condition pages connected to this study.